AIM trade ideas
AIM ImmunoTech, Inc. Trade SetupAIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
Keeping a Close Watch on AIMAIM is one of the stocks that have underwhelmed me in performance lately. However given current resistance wedges, I think as an entry point right now it would seem low to mid risk. I believe going in as a long hold, you can expect some positive retracement, and quite possibly a $3.15 price target by end of August. That being said, pursue at your own risk. As always, everything I say is on the basis of opinion.
looks like we are ready for something herePlease note: I'm just sharing my view. its not a recommendation for buying or selling.
Aim-Ready-Set-FireAim ready to boogie soon.
Not financial advice
Not a recommendation to buy this stock
AIM has the potential for huge gains!Hello,
What is AIM?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
News
May 14, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that the U.S. Food and Drug Administration has authorized the first human trial assessing the safety and effectiveness of the Company's lead asset, Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus.
My Thoughts For You
This sounds crazy but I checked the history and every time the price plummets it will retrace the wave by 78.6% to 100%. On this chart is what you are seeing but I can see this going from $90.00 to $447.00.
Good Luck, Cheers!
Be sure to comment, follow, like, and check out my profile for more trade ideas!
AIM can hit $3.85 ~ Actual TargetFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said at a buy entry now, than sell good till canceled order at $3.85, I think something like this can actually be reached quite soon. AIM started having some strong support, and you can start seeing accumulation growth, and likely at some point small cap funds will start getting interested in holding it. I am obviously bullish in this one.
AIM C&H + WedgeStock consolidating in a nicely defined wedge (log chart) that comes on the heels of a C&H breakout. Bullish bias above $2 which was prior resistance level. I am watching for the 20 SMA (blue) to cross the 50 SMA (purple), and for the MACD to remain positive and begin accelerating. OBV continues to hit ATHs as price consolidates, another bullish sign.
AIM Immunotech ready for bounce up?So, RSI is about to hit 40 level. Lets see if the price bounces off. price dropped almost 80% after a huge run up.
There is still a gap to fill at ~1.81 and ~1.20
$AIM on Monday WatchlistVery significant golden cross occurred
MACD reversed and Histogram about to cross zeroline
AIM Immunotech Inc Surges $aimEarnings highlights source yahoo
As of December 31, 2019, AIM had cash, cash equivalents and marketable securities of $8.778 million, compared with $1.825 million as of December 31, 2018.
Research and development expenses for 2019 were $4.651 million, compared with $4.778 million for 2018. General and administrative expenses for 2019 were $7.039 million, compared with $6.201 million for 2018.
The net loss from continuing operations for 2019 was $9.533 million, or $2.62 per share, compared with $9.827 million, or $9.77 per share, for 2018.
Please refer to the full 10-K for complete details.
Update on COVID-19 Pandemic Response
Since the outbreak of SARS-CoV-2 - which causes the disease COVID-19 - AIM has been actively engaged in determining whether its drug Ampligen could be an effective treatment for this virus. The company believe that prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against the new virus as both a protective prophylaxis and an early-onset therapy.
AIM has reached several significant COVID-19 milestones over the past two months:
AIM filed provisional patent applications to secure the company's intellectual property before seeking domestic and international research partners.
Japan's National Institute of Infectious Diseases (NIID) agreed to experiment with Ampligen as a potential treatment for COVID-19. The testing and research will be conducted by laboratories at the NIID and the University of Tokyo. AIM will report immediately upon receipt of results.
AIM engaged ChinaGoAbroad (CGA) to facilitate pre-clinical and clinical trials of Ampligen in the People's Republic of China (PRC).
AIM is in discussions with GP-Pharm in Argentina to advance Ampligen for potential use against COVID-19. Ampligen is an approved drug in Argentina for use against myalgic encephalomyelitis/chronic fatigue syndrome.
AIM is in discussions in The Netherlands - where Ampligen was recently used to treat pancreatic cancer patients - to explore expedited pre-clinical and clinical trials of Ampligen.
AIM is currently targeting the United States, Europe, Asia and Argentina for new clinical trials and, as necessary steps before clinical trials could begin, the company is in the process of soliciting one or more sites and qualified principal investigators in one or more countries. Protocols for potential clinical trial are in the final stages of development. AIM intends, as a next step, to as rapidly as possible seek Institutional Review Board approvals and governmental authorizations to commence the clinical trials of Ampligen as both a protective prophylaxis and an early-onset therapy.
Sometimes.....You Only Need a Solid CandleI cleaned up on this one. I got a little antsy because Robinhood has not let me trade for a week, but today was redemption. I jumped in, and gambled on the curve. Made a quick profit. I'm out for the day guys.
AIM AIM = WEDGE SISTEM MONTER VOLUME = CORONA VIRUS PLAYERS = SPONSOR OF TRUMP ILLUSIONISM FOR HEL CORONAVIRUS.. STAY TUNED FROM 1.3$ to 15$ from today to May 15th
IM IN FROM YESTERDAY 5000
AIM ImmunoTech, Inc. set to surgeAIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
Cup and handle breakoutDISCLAIMER. This post is for educational purposes only and should not be construed as investment advice. Your use of the stock observations is entirely at your own risk and it is your sole responsibility
Unusual Volume, rich catalyst program in 2020AIM
Has a Gap to fill & seen big unsual buying. Has a very Low float.
A Biotech stock targeting diffrent cancers, a lot of data due throughout 2020
- Triple-Negative Breast Cancer ; Phase 1 data due 2Q
- Colorectal cancer ; Phase 2 date due 2Q
- Ovarian cancer ; Phase 1 interim data due 1Q
- Ovarian cancer ; Phase 2 data due 4Q
